Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 5,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares in the company, valued at $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 24th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00.
• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00.

Janux Therapeutics Stock Down 12.1 %

Shares of NASDAQ JANX opened at $50.82 on Thursday. The firm’s fifty day moving average is $54.48 and its 200 day moving average is $48.16. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $71.71. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -43.44 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its stake in shares of Janux Therapeutics by 136.3% during the second quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock valued at $4,818,000 after buying an additional 66,340 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Janux Therapeutics in the second quarter valued at $151,000. Principal Financial Group Inc. purchased a new position in Janux Therapeutics during the 2nd quarter valued at $237,000. Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 41.2% in the 2nd quarter. Rhumbline Advisers now owns 38,008 shares of the company’s stock worth $1,592,000 after purchasing an additional 11,085 shares during the period. Finally, TD Asset Management Inc bought a new stake in shares of Janux Therapeutics during the 2nd quarter valued at about $829,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Leerink Partners increased their target price on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. UBS Group assumed coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. Stifel Nicolaus increased their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, Scotiabank boosted their target price on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.